Lavé T - Search Results

1

A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551.

Fleury A, Lavé T, Jonsson F, Schmitt M, Hirkaler G, Polonchuk L, Breidenbach A. Fleury A, et al. Among authors: lave t. J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):123-33. doi: 10.1016/j.vascn.2010.08.003. Epub 2010 Aug 21. J Pharmacol Toxicol Methods. 2011. PMID: 20732434

2

Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.

Caruso A, Frances N, Meille C, Greiter-Wilke A, Hillebrecht A, Lavé T. Caruso A, et al. Among authors: lave t. J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):73-85. doi: 10.1016/j.vascn.2014.05.004. Epub 2014 May 28. J Pharmacol Toxicol Methods. 2014. PMID: 24879942

3

Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor.

Lavé T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta MA, Schmitt M. Lavé T, et al. J Pharm Pharmacol. 1999 Jan;51(1):85-91. doi: 10.1211/0022357991772006. J Pharm Pharmacol. 1999. PMID: 10197423

4

Challenges and opportunities with modelling and simulation in drug discovery and drug development.

Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M. Lavé T, et al. Xenobiotica. 2007 Oct-Nov;37(10-11):1295-310. doi: 10.1080/00498250701534885. Xenobiotica. 2007. PMID: 17968746

5

Recent developments in using mechanistic cardiac modelling for drug safety evaluation.

Davies MR, Wang K, Mirams GR, Caruso A, Noble D, Walz A, Lavé T, Schuler F, Singer T, Polonchuk L. Davies MR, et al. Among authors: lave t. Drug Discov Today. 2016 Jun;21(6):924-38. doi: 10.1016/j.drudis.2016.02.003. Epub 2016 Feb 15. Drug Discov Today. 2016. PMID: 26891981 Free PMC article. Review.

6

Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk.

Davies MR, Martinec M, Walls R, Schwarz R, Mirams GR, Wang K, Steiner G, Surinach A, Flores C, Lavé T, Singer T, Polonchuk L. Davies MR, et al. Among authors: lave t. Cell Rep Med. 2020 Aug 25;1(5):100076. doi: 10.1016/j.xcrm.2020.100076. eCollection 2020 Aug 25. Cell Rep Med. 2020. PMID: 33205069 Free PMC article.

7

Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans.

Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, Coassolo P. Lave T, et al. Xenobiotica. 1996 Aug;26(8):839-51. doi: 10.3109/00498259609046754. Xenobiotica. 1996. PMID: 8879148

8

Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.

Reddy MB, Morcos PN, Le Pogam S, Ou Y, Frank K, Lave T, Smith P. Reddy MB, et al. Among authors: lave t. Antimicrob Agents Chemother. 2012 Jun;56(6):3144-56. doi: 10.1128/AAC.06283-11. Epub 2012 Apr 2. Antimicrob Agents Chemother. 2012. PMID: 22470110 Free PMC article.

9

Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.

Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC. Lave T, et al. J Pharm Pharmacol. 1996 Jun;48(6):573-7. doi: 10.1111/j.2042-7158.1996.tb05976.x. J Pharm Pharmacol. 1996. PMID: 8832489

10

Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Jones HM, Parrott N, Ohlenbusch G, Lavé T. Jones HM, et al. Among authors: lave t. Clin Pharmacokinet. 2006;45(12):1213-26. doi: 10.2165/00003088-200645120-00006. Clin Pharmacokinet. 2006. PMID: 17112297

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters